12931_2024_2822_MOESM1_ESM.docx (29.25 kB)
Additional file 1 of Statins did not reduce the frequency of exacerbations in individuals with COPD and cardiovascular comorbidities in the COSYCONET cohort
journal contribution
posted on 2024-05-16, 03:41 authored by N. Frantzi, X. P. Nguyen, C. Herr, P. Alter, S. Söhler, D. Soriano, H. Watz, B. Waschki, F. Trinkmann, M. Eichenlaub, F. C. Trudzinski, J. D. Michels-Zetsche, A. Omlor, F. Seiler, I. Moneke, F. Biertz, G. Rohde, D. Stolz, T. Welte, H. U. Kauczor, K. Kahnert, R. A. Jörres, C. F. Vogelmeier, R. Bals, S. FähndrichAdditional file 1: Supplemental Table S1: Results of (logistic) GEE analyses on the occurrence of at least one exacerbation using data over the course of 4.5 years (visits V1-V5). Only patients who maintained in the study until visit V5 were included. As predictors each analysis comprised one of the comorbidities, the presence of statins and an interaction term between these two factors, as well as the covariates age, sex, BMI, GOLD grade and pack-years. The table shows the odds ratios (OR) and their 95% confidence intervals (95% CI) regarding comorbidities (left column), statins (middle column) and the interaction (right column) for each of the analyses. Supplemental Table S2: Results of (logistic) GEE analyses on the occurrence of at least one severe exacerbation using data over the course of 4.5 years (visits V1-V5). Only patients who maintained in the study until visit V5 were included. As predictors each analysis comprised one of the comorbidities, the presence of statins and an interaction term between these two factors, as well as the covariates age, sex, BMI, GOLD grade and pack-years. The table shows the odds ratios (OR) and their 95% confidence intervals (95% CI) regarding comorbidities (left column), statins (middle column) and the interaction (right column) for each of the analyses.
